Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

3.5K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.5K
Epigenetic Regulation01:46

Epigenetic Regulation

28.7K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
28.7K
Epigenetic Regulation01:46

Epigenetic Regulation

24.1K
24.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.1K
6.1K
Histone Modification02:32

Histone Modification

14.6K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
14.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Dosages for First-in-Human Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs.

Clinical pharmacology and therapeutics·2025
Same author

Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Related Experiment Video

Updated: May 2, 2026

Methylated DNA Immunoprecipitation
21:24

Methylated DNA Immunoprecipitation

Published on: January 2, 2009

23.5K

Epigenetics and oncology.

Padmaja Mummaneni1, Stacy S Shord

  • 1Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland.

Pharmacotherapy
|March 13, 2014
PubMed
Summary

Epigenetic modifications drive cancer development and drug resistance. Epigenome-targeted therapies and diagnostics show promise, with ongoing research focusing on combination treatments and biomarker discovery for improved cancer care.

Keywords:
epigeneticsoncologytargeted therapy

More Related Videos

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

10.0K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

6.6K

Related Experiment Videos

Last Updated: May 2, 2026

Methylated DNA Immunoprecipitation
21:24

Methylated DNA Immunoprecipitation

Published on: January 2, 2009

23.5K
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

10.0K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

6.6K

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Epigenetic modifications are crucial in normal cell malignant transformation and cancer development.
  • These changes influence cancer progression and the emergence of drug resistance.

Purpose of the Study:

  • To review the role of epigenetic modifications in cancer development and drug resistance.
  • To describe the progress and challenges in developing epigenome-targeted anticancer drugs and diagnostic tools.

Main Methods:

  • Literature review of epigenetic modifications in cancer.
  • Analysis of FDA-approved epigenome-targeted therapies (DNA methyltransferase and histone deacetylase inhibitors).
  • Discussion of diagnostic applications and future directions in epigenome-targeted drug development.

Main Results:

  • Four epigenome-targeted drugs (azacitidine, decitabine, vorinostat, romidepsin) are FDA-approved, primarily for hematologic malignancies.
  • Epigenetic modifications serve as biomarkers for cancer diagnosis, patient stratification, and drug dosage selection.
  • Combination therapies are a focus for expanding treatment options.

Conclusions:

  • Epigenome-targeted therapies offer a promising avenue for cancer treatment, with initial success in specific malignancies.
  • Further research is needed to translate epigenetic knowledge into novel anticancer drugs and advanced diagnostic tools.
  • Addressing remaining questions is key for advancing epigenome-based cancer therapies.